Brief: Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. Tariffs
04/04/2025 24:00
April 3 (Reuters) - Mesoblast Ltd MSB.AX: MESOBLAST ALLOGENEIC CELL THERAPY PRODUCTS ARE DESIGNATED ‘U.S. COUNTRY OF ORIGIN’ AND NOT SUBJECT TO U.S. TARIFFS Source text: ID:nGNX1QhS1R Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M